Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has announced that a meeting of the Board of Directors will be held on Thursday, January 22, 2026. The primary agenda for this meeting is to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2025.

In accordance with the company's "Code of Conduct for Prevention of Insider Trading" and SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window for designated persons will remain closed. This closure is effective from December 31, 2025, to January 24, 2026, inclusive, to facilitate the approval of the aforementioned financial results.